The DNA damage response and cancer therapy

Nature

Volumn 481, Issue 7381, 2012, Pages 287-294

  Lord, Christopher J ^a   Ashworth, Alan ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOBENZAMIDE; 8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; ATM PROTEIN; AZD 7762; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE DERIVATIVE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; IMETELSTAT; IRINOTECAN; LOMEGUATRIB; METHOTREXATE; MITOMYCIN C; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NIRAPARIB; OLAPARIB; OXALIPLATIN; PACLITAXEL; PROTEIN MLH1; PROTEIN MSH2; RUCAPARIB; TAXANE DERIVATIVE; TEMOZOLOMIDE; TUMOR MARKER; UNCLASSIFIED DRUG; VELIPARIB;

CANCER; CYTOLOGY; GENETIC ANALYSIS; GENOMICS; TUMOR;

BREAST CANCER; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE; DAUGHTER CELL; DNA REPAIR; DNA STRAND BREAKAGE; GENE MUTATION; GENETIC ANALYSIS; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; MOLECULARLY TARGETED THERAPY; NERVE CELL; OVARY CANCER; PRIORITY JOURNAL; REVIEW; TUMOR CELL; TUMOR SUPPRESSOR GENE;

DNA DAMAGE; DNA REPAIR; GENOMIC INSTABILITY; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOPLASTIC STEM CELLS; POLY(ADP-RIBOSE) POLYMERASES; TUMOR MICROENVIRONMENT;

EID: 84856019858     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature10760     Document Type: Review

References (73)

1. Boveri, T. Zur Frage der Entstehung Maligner Tumoren (Gustav Fischer, 1914).
2. Boveri, T. Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris. J. Cell Sci. 121, 1-84 (2008).
3. Ciccia, A. & Elledge, S. J. The DNA damage response: making it safe to play with knives. Mol. Cell 40, 179-204 (2010).
4. Hoeijmakers, J. H. DNA damage, aging, and cancer. N. Engl. J. Med. 361, 1475-1485 (2009).
5. Phillips, D. H., Hewer, A., Martin, C. N., Garner, R. C. & King, M. M. Correlation of DNA adduct levels in human lung with cigarette smoking. Nature 336, 790-792 (1988). (Pubitemid 19014441)
6. David, S. S., O'Shea, V. L. & Kundu, S. Base-excision repair of oxidative DNA damage. Nature 447, 941-950 (2007). (Pubitemid 46975761)
7. Nakabeppu, Y. et al. Mutagenesis and carcinogenesis caused by the oxidation of nucleic acids. Biol. Chem. 387, 373-379 (2006).
8. Cleaver, J. E., Lam, E. T. & Revet, I. Disorders of nucleotide excision repair: the genetic and molecular basis of heterogeneity. Nature Rev. Genet. 10, 756-768 (2009).
9. Moynahan, M. E. & Jasin, M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nature Rev. Mol. Cell Biol. 11, 196-207 (2010).
10. Lieber, M. R. NHEJ and its backup pathways in chromosomal translocations. Nature Struct. Mol. Biol. 17, 393-395 (2010).
11. Jiricny, J. The multifaceted mismatch-repair system. Nature Rev. Mol. Cell Biol 7, 335-346 (2006).
12. Artandi, S. E. & DePinho, R. A. Telomeres and telomerase in cancer. Carcinogenesis 31, 9-18 (2010).
13. Stephens, P. J. et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144, 27-40 (2011).
14. Bell, O., Tiwari, V. K., Thoma, N. H. & Schubeler, D. Determinants and dynamics of genome accessibility. Nature Rev. Genet. 12, 554-564 (2011).
15. Warmerdam, D. O. & Kanaar, R. Dealing with DNA damage: relationships between checkpoint and repair pathways. Mutat. Res. 704, 2-11 (2010).
16. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
17. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011).
18. Bartkova, J. et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444, 633-637 (2006). (Pubitemid 44864442)
19. Halazonetis, T. D., Gorgoulis, V. G. & Bartek, J. An oncogene-induced DNA damage model for cancer development. Science 319, 1352-1355 (2008). (Pubitemid 351354863)
20. Turner, N., Tutt, A. & Ashworth, A. Hallmarks of 'BRCAness' in sporadic cancers. Nature Rev. Cancer 4, 814-819 (2004). (Pubitemid 39331153)
21. Banerjee, S., Kaye, S. B. & Ashworth, A. Making the best of PARP inhibitors inovarian cancer. Nature Rev. Clin. Oncol. 7, 508-519 (2010).
22. Friboulet, L. et al. Molecular characteristics of ERCC1-negative versus ERCC1-positive tumors in resected NSCLC. Clin. Cancer Res. 17, 5562-5572 (2011).
23. Weller, M. et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nature Rev. Neurol. 6, 39-51 (2010).
24. Pommier, Y., Leo, E., Zhang, H. & Marchand, C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem. Biol. 17, 421-433 (2010).
25. Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H. & Poirier, G. G. PARP inhibition: PARP1 and beyond. Nature Rev. Cancer 10, 293-301 (2010).
26. Zaremba, T. & Curtin, N. J. PARP inhibitor development for systemic cancer targeting. Anticancer Agents Med. Chem. 7, 515-523 (2007). (Pubitemid 351836123)
27. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005). (Pubitemid 40559006)
28. Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917 (2005). (Pubitemid 40559005)
29. Lord, C. J. & Ashworth, A. Targeted therapy for cancer using PARP inhibitors. Curr. Opin. Pharmacol. 8, 363-369 (2008).
30. Dobzhansky, T. Genetics of natural populations. Xiii. Recombination and variability in populations of drosophila pseudoobscura. Genetics 31, 269-290 (1946).
31. Lucchesi, J. C. Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanogaster. Genetics 59, 37-44 (1968).
32. Hartwell, L. H., Szankasi, P., Roberts, C. J., Murray, A. W. & Friend, S. H. Integrating genetic approaches into the discovery of anticancer drugs. Science 278, 1064-1068 (1997). (Pubitemid 27517876)
33. Kaelin, W. G. Jr. Synthetic lethality: a framework for the development of wiser cancer therapeutics. Genome Med. 1, 99 (2009).
34. Issaeva, N. et al. 6-Thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res. 70, 6268-6276 (2010).
35. Martin, S. A. et al. DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell 17, 235-248 (2010).
36. Martin, S. A., Hewish, M., Sims, D., Lord, C. J. & Ashworth, A. Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers. Cancer Res. 71, 1836-1848 (2011).
37. Martin, S. A. et al. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol. Med. 1, 323-337 (2009).
38. Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134 (2009).
39. Balmaña, J., Domchek, S. M., Tutt, A. & Garber, J. E. Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers. Cancer Discov. 1, 29-34 (2011).
40. Mendeleyev, J., Kirsten, E., Hakam, A., Buki, K. G. & Kun, E. Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture. Biochem. Pharmacol. 50, 705-714 (1995).
41. Liu, X. et al. Iniparib non-selectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin. Cancer Res. advance ahead of print http://dx.doi.org/10.1158/1078-0432.CCR-11-1973 (29 November 2011).
42. McCabe, N. et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66, 8109-8115 (2006). (Pubitemid 44299177)
43. Peasland, A. et al. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br. J. Cancer 105, 372-381 (2011).
44. Murai, J. et al. The USP1/UAF1 complex promotes double-strand break repair through homologous recombination. Mol. Cell. Biol. 31, 2462-2469 (2011).
45. Moskwa, P. et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol. Cell 41, 210-220 (2011).
46. Johnson, N. et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nature Med. 17, 875-882 (2011).
47. Akamatsu, Y. & Jasin, M. Role for the mammalian Swi5?Sfr1 complex in DNA strand break repair through homologous recombination. PLoS Genet. 6, e1001160 (2010).
48. Mendes-Pereira, A. M. et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 1, 315-322 (2009).
49. Brenner, J. C. et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19, 664-678 (2011).
50. Edwards, S. L. et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451, 1111-1115 (2008). (Pubitemid 351317441)
51. Sakai, W. et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451, 1116-1120 (2008). (Pubitemid 351317449)
52. Sakai, W. et al. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res. 69, 6381-6386 (2009).
53. Swisher, E. M. et al. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 68, 2581-2586 (2008). (Pubitemid 351556255)
54. Norquist, B. et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J. Clin. Oncol. 29, 3008-3015 (2011).
55. Rottenberg, S. et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl Acad. Sci. USA 105, 17079-17084 (2008).
56. Bouwman, P. et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nature Struct. Mol. Biol. 17, 688-695 (2010).
57. Bunting, S. F. et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141, 243-254 (2010).
58. Jiang, H. et al. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev. 23, 1895-1909 (2009).
59. Galanty, Y. et al. Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature 462, 935-939 (2009).
60. Soucy, T. A. et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458, 732-736 (2009).
61. Lansdorp, P. M. Immortal strands? Give me a break. Cell 129, 1244-1247 (2007). (Pubitemid 46962099)
62. Diehn, M. et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458, 780-783 (2009).
63. Zhang, M., Atkinson, R. L. & Rosen, J. M. Selective targeting of radiation-resistant tumor-initiating cells. Proc. Natl Acad. Sci. USA 107, 3522-3527 (2010).
64. Singh, S. K. et al. Identification of human brain tumour initiating cells. Nature 432, 396-401 (2004). (Pubitemid 39551674)
65. Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760 (2006). (Pubitemid 44949604)
66. Mantoni, T. S., Lunardi, S., Al-Assar, O., Masamune, A. & Brunner, T. B. Pancreatic stellate cells radioprotect pancreatic cancer cells through beta 1-integrin signaling. Cancer Res. 71, 3453-3458 (2011).
67. Stratton, M. R. Exploring the genomes of cancer cells: progress and promise. Science 331, 1553-1558 (2011).
68. Stephens, P. J. et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462, 1005-1010 (2009).
69. Barber, L. J. et al. Comprehensive genomic analysis of a BRCA2 deficient human pancreatic cancer. PLoS ONE 6, e21639 (2011).
70. Graeser, M. et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin. Cancer Res. 16, 6159-6168 (2010).
71. Polo, S. E. & Jackson, S. P. Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications. Genes Dev. 25, 409-433 (2011).
72. Hoeijmakers, J. H. Genome maintenance mechanisms for preventing cancer. Nature 411, 366-374 (2001). (Pubitemid 32467046)
73. Liu, P. et al. Chromosome catastrophes involve replication mechanisms generating complex genomic rearrangements. Cell 146, 889-903 (2011).